Core Viewpoint - The fourth Synthetic Biology and Green Bio-Manufacturing Conference (SynBioCon 2025) will be held from August 20-22 in Ningbo, Zhejiang, focusing on the integration of AI with bio-manufacturing, green chemicals, new materials, future food, and agriculture [4][5]. Group 1: Conference Overview - The conference will explore the development trends of the bio-manufacturing industry during the 14th Five-Year Plan, innovations driven by AI, and the technologies and products that will sustain the vitality of the bio-manufacturing sector [4][5]. - Various activities will be held concurrently, including a Youth Forum on Bio-Manufacturing, a high-level roundtable discussion, and a closed-door seminar on the "2025 AI Empowering Bio-Manufacturing Industry Innovation Development Blue Book" [4][5]. Group 2: Agenda Highlights - Day 1 will feature registration, a high-level roundtable discussion, and a Youth Forum focused on discovering innovations in bio-manufacturing [7][10]. - Day 2 will include an opening ceremony, a macro forum on the bio-manufacturing industry, and specialized forums on green chemicals and new materials, as well as a welcome dinner [8][9]. - Day 3 will focus on AI applications in bio-manufacturing, future food, and agriculture, along with technology showcases and networking opportunities [8][28]. Group 3: Supporting Organizations - The conference is organized by Ningbo Detaizhong Research Information Technology Co., Ltd. and supported by various institutions, including Peking University Ningbo Institute of Ocean Medicine and the Zhejiang Synthetic Biology Industry Technology Alliance [5][6]. - Notable experts and organizations are involved, including Zhang Xian'en from Shenzhen University and multiple biotechnology companies [5][6]. Group 4: Industry Insights - The conference will release the "China Synthetic Biology Industry Distribution Map (2025 Edition)" and a list of over 500 representative enterprises in the bio-manufacturing sector [65][66]. - The event aims to facilitate the transfer and transformation of scientific achievements, product scaling, and talent acquisition in the bio-manufacturing industry [4][5].

Core Viewpoint - The SynBioCon 2025 conference aims to facilitate the transformation of scientific achievements into practical applications, focusing on the development of the synthetic biology and green manufacturing industries [2][14]. Group 1: Conference Overview - The fourth Synthetic Biology and Green Manufacturing Conference (SynBioCon 2025) will be held from August 20-22 in Ningbo, Zhejiang [2][14]. - The conference is organized by DT New Materials, with support from various academic and industry organizations, including Peking University Ningbo Institute of Oceanography and Enzyme Bio [2][14]. - The event will focus on the integration of AI with biological manufacturing, green chemicals, new materials, future food, and agriculture [14]. Group 2: Key Activities - The conference will feature a series of activities, including a youth forum on biological manufacturing, a high-level industry roundtable, and a closed-door seminar on the "2025 Blue Book for AI Empowering Biological Manufacturing Industry" [14][15]. - A special event will showcase 100 innovative achievements in synthetic biological manufacturing to promote efficient technology transfer [2][14]. Group 3: Featured Project - One highlighted project is the biological preparation technology for functional sugars and dietary fibers led by Professor Wu Jing's team from Jiangnan University [6][7]. - Functional sugars and dietary fibers are essential components in modern food industry, offering health benefits such as low calories and regulation of gut microbiota [7]. - The project utilizes enzyme catalysis for the production of various functional sugars and dietary fibers, establishing a cost-effective and efficient green production technology [8][9].

Group 1 - The core idea of the articles revolves around the innovative production of allulose sugar by Weiyuan Synthetic Biotechnology, utilizing advanced biosynthesis technology to reduce production costs and improve efficiency [1] - Allulose sugar is a natural sweetener with almost no calories, aiding in blood sugar control and weight management, and its production has been simplified from a two-step to a one-step process, increasing conversion efficiency from 10% to over 80% [1] - The first phase of the allulose sugar factory has been officially put into production, with an annual capacity reaching 10,000 tons [1] Group 2 - Changping District is focusing on developing a cluster of synthetic biology manufacturing enterprises, with over 120 companies gathered in the area, aiming for an industry revenue exceeding 6 billion yuan in 2024 [2] - The district is positioning itself as an innovation source and industry leader in synthetic biology manufacturing, with significant breakthroughs in various fields such as biobased new materials and gas fermentation [2]

Group 1 - The company Micro Yuan Synthetic Biotechnology (Beijing) Co., Ltd. is innovating in biosynthesis technology to produce allulose, a low-calorie sweetener that helps with blood sugar control and weight management [1] - Allulose production has been optimized from a two-step reaction to a one-step process, increasing conversion efficiency from 10% to over 80%, and reducing production costs by approximately 50% [1] - The first phase of the allulose production facility has been officially launched, with an annual production capacity reaching tens of thousands of tons [1] Group 2 - Changping District is focusing on developing synthetic biology manufacturing, with over 120 companies in the sector and projected industry revenue exceeding 6 billion yuan in 2024 [2] - The district aims to become a leading hub for synthetic biology innovation and has attracted significant investment in various subfields, including biobased materials and gas fermentation [2] - Notable companies in the area include Jitai Laibo Biotechnology and Qihe Biotechnology, which are making significant advancements in carbon fixation and plant cell gene editing, respectively [2]

Core Insights - The SynBioCon 2025 conference will be held from August 20-22 in Ningbo, Zhejiang, focusing on the transformation of scientific achievements and the development of the synthetic biology industry [2][13] - The conference aims to facilitate over 1000 connections between research institutions and startups, showcasing 100 innovative synthetic biology manufacturing technologies [2][10] Event Overview - The conference is organized by DT New Materials, with support from various academic and industry organizations, including Peking University and the China Society of Biotechnology [2][13] - Key themes include AI in biological manufacturing, green chemistry, new materials, future food, and agriculture [13] Featured Technology - Hydroxy Rosavin, a derivative of Rosavin, shows promise in anti-fatigue, anti-aging, anti-tumor, and anti-radiation applications, with a production yield of 2.5 g/L and a molar conversion rate of 78% [7][9] - The technology utilizes advanced enzyme screening and directed evolution to create a yeast cell factory for production [7][12] Intellectual Property - The project has several patents related to the production of Hydroxy Rosavin, including recombinant plasmids and gene-engineered strains [8] Collaboration Opportunities - The Hydroxy Rosavin project is supported by the Chongqing Natural Science Foundation and seeks investment from relevant enterprises to accelerate industrialization [9] Conference Activities - The conference will feature a "Technology Achievement Exhibition and Matching" session, inviting 100 innovative projects for display and industry connection [10][14] - Additional activities include a youth forum, high-level discussions, and a closed-door seminar on AI's role in biological manufacturing [13][14]

Core Viewpoint - The article discusses the 2026 Regional Joint Fund (Beijing) project guidelines, focusing on key industries in Haidian District and Beijing Economic-Technological Development Area, with specific funding allocations for integrated and key projects [1][8]. Group 1: Key Areas of Focus - The guidelines emphasize several key areas for funding, including: - Electronic Information: Integrated circuits, artificial intelligence, wireless communication, and quantum information [2][3]. - Life and Health: Synthetic biology manufacturing, cell and gene therapy, brain science, biomedical engineering, and smart healthcare [3]. - New Materials and Advanced Manufacturing: Robotics, new materials, and intelligent equipment [3]. - Modern Transportation and Aerospace: New energy and intelligent connected vehicles, and aerospace industry [3]. Group 2: Guidelines Requirements - The guidelines require that the proposed needs must meet specific criteria: - Scientific focus on fundamental scientific issues behind technological challenges, avoiding mere technical applications [4]. - Inclusivity without overly restrictive elements, ensuring a balance between specificity and broad applicability [5]. - Directionality that aligns closely with the development needs of Haidian District and Beijing Economic-Technological Development Area [5]. - Safety compliance with national laws and ethical standards, emphasizing the prevention of biological and information security risks [6]. - Innovation to avoid duplication with existing guidelines from national and municipal science funds [6]. Group 3: Submission Requirements - Proposers must meet certain conditions: - The proposing unit must be a supporting unit of the Beijing Natural Science Foundation [7]. - Experience in leading key national science fund projects is required [8]. - Each proposer can submit only one guideline request, and each company can participate in up to two requests [8].

Core Insights - The establishment of Hefei Ian Biotechnology Co., Ltd. with a registered capital of 10 million yuan focuses on the manufacturing and research of bio-based materials, indicating a growing interest in sustainable materials in the industry [1][3]. Group 1: Company Overview - Enhe Biotechnology, founded in 2019 and headquartered in Hangzhou, has become a prominent player in the capital market, utilizing a high-throughput experimental platform to optimize biological engineering for industrial applications [3][4]. - The company has completed over $145 million in financing by 2025 and was recognized as one of the "50 Smartest Companies" by MIT Technology Review in 2020 [4]. Group 2: Strategic Collaborations - In May 2023, a strategic partnership was formed between domestic beauty giant Proya and Enhe Biotechnology, focusing on AI-driven bio-manufacturing technologies for cosmetic ingredient development [5][7]. - This collaboration aims to innovate in the realm of bioactive ingredients for cosmetics, promoting a shift towards efficiency, safety, and sustainability in the beauty industry [7]. Group 3: Industry Movements - Yili Group, a leading dairy company in China, is venturing into synthetic biology, seeking investment opportunities in early-stage innovative companies within the health food sector [8][10]. - Yili has established a venture capital fund with a total subscription amount of 20 million yuan, focusing on high-tech innovations in the health sector, particularly in food science and life sciences [10][11]. Group 4: Sustainability Initiatives - Yili has been actively pursuing sustainable development, as evidenced by its collaboration with Xampla to test a new plant-based packaging material aimed at preserving nutrients in dairy products [12][15]. - The company emphasizes a commitment to a sustainable future while achieving steady business growth [15]. Group 5: Upcoming Events - The 2025 Synthetic Biology and Green Bio-Manufacturing Conference (SynBioCon 2025) will be held from August 20-22 in Ningbo, Zhejiang, focusing on AI and bio-manufacturing, green chemicals, new materials, future food, and agriculture [17][19]. - The conference will feature various activities, including forums, discussions, and showcases of synthetic biology innovations [17][18].

Core Insights - The article highlights the advancements in synthetic biology, particularly through gene editing technologies, which are revolutionizing the production of valuable metabolites and agricultural products, significantly impacting industries such as medicine and agriculture [1][2][5]. Group 1: Synthetic Biology and Gene Editing - The use of genetically engineered yeast to produce artemisinin has demonstrated the potential to replace the extraction from 50,000 acres of Artemisia annua cultivation, benefiting millions of malaria patients in developing countries since 2013 [1]. - Beijing Qihe Biotechnology Co., a representative company in the synthetic biology sector, has achieved a significant increase in oil content in soybeans from over 20% to above 80% through precise gene editing [2]. - The gene editing technology allows for rapid breeding cycles, reducing the time needed to develop disease-resistant traits in crops like wheat from decades to approximately three months [2][3]. Group 2: Innovation Centers and Industrialization - The Beijing Synthetic Biology Manufacturing Technology Innovation Center, established by the local government and Beijing University of Chemical Technology, serves as a core platform for technological innovation in the synthetic biology industry [4]. - The center focuses on comprehensive technological breakthroughs across the entire biological manufacturing value chain, with five research teams already operational [4][6]. - The shift from traditional petrochemical methods to biological production of materials like adipic acid is highlighted as a key step towards a greener, more sustainable industry, with significant reductions in greenhouse gas emissions [4][5]. Group 3: Industry Growth and Future Prospects - The synthetic biology sector is projected to create an economic value of $30 trillion, with an expected global production scale reaching $2 trillion to $4 trillion by 2030 [7]. - The Changping District has established a cluster of over 120 synthetic biology manufacturing companies, with projected revenues exceeding 6 billion yuan in 2024 and significant investments in fixed assets [8]. - Recent policy measures in Changping aim to support the high-quality development of the synthetic biology industry, emphasizing integrated policies and collaborative efforts across the sector [7][8].

Core Viewpoint - Changde City has passed the "Regulations on Promoting the Development of Synthetic Biology Manufacturing Industry," marking the first local legislation in China for this sector, aimed at enhancing the development of synthetic biology manufacturing as a strategic emerging industry [1][2]. Summary by Sections Legislative Background - The "Regulations" are part of a broader initiative to support the high-quality development of the synthetic biology manufacturing industry in Changde, which has been recognized as a key area for new productive forces and strategic emerging industries [2][4]. Industry Development Measures - In February, the Hunan Provincial Government issued measures to support Changde's synthetic biology manufacturing, focusing on areas such as enzyme preparations, pharmaceutical intermediates, agricultural chemicals, future foods, health products, and bio-based materials [4]. Legislative Process - The legislative project for promoting synthetic biology manufacturing began in September 2024, with multiple reviews and revisions leading to the final draft of the "Regulations," which consists of 19 articles addressing various aspects of industry development [5][6]. Key Provisions of the Regulations - The first three articles outline the legislative purpose, scope, and responsibilities of government departments. Articles four to fifteen focus on core industry development issues, including enhancing investment attraction, R&D capabilities, and talent acquisition, while also addressing high operational costs and approval efficiency [6]. - Article sixteen introduces a "no penalty for two situations, four prohibitions" system to optimize the business environment, while article seventeen establishes a fault-tolerance mechanism [6]. Next Steps - The Changde Municipal People's Congress will submit the "Regulations" to the Provincial People's Congress for approval, after which it will be published and implemented [6]. Upcoming Events - The Fourth Synthetic Biology and Green Manufacturing Conference will be held in Ningbo from August 20-22, focusing on AI and biological manufacturing, with discussions on trends and innovations in the industry [7][9].

Core Insights - Synthetic biology is recognized as the "third biotechnology revolution," following the discovery of the DNA double helix and the Human Genome Project, and is becoming a focal point in global technological competition [1] - It is predicted that 70% of future products will be derived from biological methods [1] Group 1: Industry Developments - Beijing has achieved multiple breakthroughs in synthetic biology manufacturing, with applications in biomedicine, beauty economy, chemical energy, and agriculture [1] - The synthetic biology manufacturing industry in Changping District generated over 6 billion yuan in revenue last year [6] - The Changping District has gathered over 120 synthetic biology companies, with projected revenue exceeding 6 billion yuan in 2024 and fixed asset investments surpassing 4.3 billion yuan [7] Group 2: Company Innovations - Microgen Synthetic, established in December 2021, is one of the earliest teams in China engaged in synthetic biology research and industrialization [3] - The company has developed a one-step fermentation method for producing allulose, achieving over 80% conversion rate and significantly reducing production costs [4] - The company has also established an engineering scale-up center and a small-scale flexible production base in Qinhuangdao, which are now operational [5] Group 3: Technological Advancements - Synthetic biology manufacturing addresses high energy consumption and pollution in chemical production, as well as low efficiency and high costs in agricultural planting [2] - Beijing has made significant advancements in key technologies such as carbon conversion and chassis cell design, leading to innovative products like high-efficiency DNA insertion technology and bio-based adipic acid production [8]